Dergiler / Nöropsikiyatri Arşivi / 2019 / Cilt: 56 - Sayı: 4

12/15 Lipoxygenase as a Therapeutic Target in Brain Disorders

Beyin Hastalıklarında Tedavi Hedefi: 12/15 Lipoksijenaz

Sayfa
288–291
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Here we reviewed 12/15-LOX chemistry shortly, and the diseases in which 12/15-LOX has a role in their pathophysiology and recent advances of 12/15-LOX inhibitors as a treatment option for neurological diseases

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Lipoxygenases are a family of lipid-oxidizing enzymes, which generate eicosanoids and related compounds from arachidonic acid and other polyunsaturated fatty acids.
📊
Temel Bulgular & Veri:The 12/15-lipoxygenase (LOX) is special in that it can directly oxidize lipid membranes containing polyunsaturated fatty acids, without the preceding action of a phospholipase, leading to the direct attack on membranous organelles, such as mitochondria.
💡
Sonuç & Katkı:Here we reviewed 12/15-LOX chemistry shortly, and the diseases in which 12/15-LOX has a role in their pathophysiology and recent advances of 12/15-LOX inhibitors as a treatment option for neurological diseases
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Lipoxygenases are a family of lipid-oxidizing enzymes, which generate eicosanoids and related compounds from arachidonic acid and other polyunsaturated fatty acids. These metabolites play important roles in physiology and pathogenesis of host defense mechanisms, cardiovascular diseases, cancer, inflammatory, allergic and neurodegenerative diseases. The 12/15-lipoxygenase (LOX) is special in that it can directly oxidize lipid membranes containing polyunsaturated fatty acids, without the preceding action of a phospholipase, leading to the direct attack on membranous organelles, such as mitochondria. The cytotoxic activity of human 12/15-LOX is up-regulated in neurons and endothelial cells especially after a stroke and thought to contribute to both neuronal cell death and blood-brain barrier leakage. The discovery of inhibitors that selectively target recombinant 12/15-LOX in vitro, as well as possessing activity against the murine orthologous ex vivo, could potentially support a novel therapeutic strategy for the treatment of stroke and other brain disorders related to 12/15-LOX. Here we reviewed 12/15-LOX chemistry shortly, and the diseases in which 12/15-LOX has a role in their pathophysiology and recent advances of 12/15-LOX inhibitors as a treatment option for neurological diseases

Abstract

Lipoksijenazlar, araşidonik asit ve diğer çoklu doymamış yağ asitlerinden eikosanoid ve ilgili bileşikleri üreten lipit oksitleyici enzim ailesindendir. Bu metabolitler konak savunma mekanizmaları, kardiyovasküler hastalıklar, kanser, inflamatuvar, alerjik ve nörodejeneratif hastalıklar gibi birçok hastalığın patogenezinde önemli rol oynar. 12/15-lipoksijenaz (LOX), bir fosfolipazın etkisine maruz kalmaksızın, çoklu doymamış yağ asitleri içeren lipit membranları doğrudan okside edebilmesi nedeniyle ve dolayısıyla mitokondri gibi membranöz organeller üzerinde doğrudan saldırıya yol açması bakımından özeldir. İnmeden sonra 12/15-LOX’un sitotoksik aktivitesi, nöronlarda ve endotel hücrelerinde artar ve hem nöronal hücre ölümüne hem de kan-beyin bariyeri sızıntısına katkıda bulunur. Seçici olarak rekombinant 12/15-LOX’u hedefleyen in vitro ve murin ortoloğuna karşı ex vivo geliştirilen inhibitörlerin keşfi, 12/15-LOX ile ilişkili inme ve diğer beyin hastalıklarının tedavisi için yeni bir terapötik stratejiyi gündeme getirmiştir. Bu derleme yazısında 12/15-LOX biyokimyasından kısaca bahsedildikten sonra, ardından 12/15-LOX’un patofizyolojisinde rol oynadığı hastalıklar ve 12/15-LOX inhibitörlerinin nörolojik hastalıklar için bir tedavi seçeneği olarak incelendiği son çalışmalar gözden geçirilmiştir.

🔖

Bu Makaleye Atıf Yap

KARATAŞ, H., AKTAS, C. C. (2019). 12/15 Lipoxygenase as a Therapeutic Target in Brain Disorders. Nöropsikiyatri Arşivi, Cilt: 56 - Sayı: 4, 288–291. https://ajindex.com/articles/292210

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Kuhn H, Banthiya S, van Leyen K.Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta. 2015 Apr
  2. 1851(4):308-30. [CrossRef ] 2. Steinhilber, D. (Ed.). (2016). Lipoxygenases in Inflammation. Springer International Publishing. ISBN 978-3-319-27766-0, [CrossRef ] 3. Hamberg M, Samuelsson B. Prostaglandin Endoperoxides. Novel Transformations of Arachidonic Acid in Human Platelets. Proc Natl Acad Sci 1974
  3. 3400–3404. [CrossRef ] 4. Schewe T, Halangk W, Hiebsch C, Rapoport SM. A lipoxygenase in rabbit reticulocytes which attacks phospholipids and intact mitochondria. FEBS Lett 1975
  4. 149–152. [CrossRef ] 5. Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta 2015
  5. 331–339. [CrossRef ] 6. Ivanov I, Heydeck D, Hofheinz K, Roffeis J, O’Donnell VB, Kuhn H, Walther M. Molecular enzymology of lipoxygenases. Arch Biochem Biophys 2010
  6. 161–174. [CrossRef ] 7. Johnson EN, Brass LF, Funk CD, Samuelsson B, Tryggvason K, Haeggström JZ. Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc Natl Acad Sci 1998
  7. 3100–3105. [CrossRef ] 8. Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, Nadler JL. Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res 2011
  8. 115–131. [CrossRef ] 9. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Hearth Association Statistics Committee, Stroke Statistics Subcommittee. Executive Summary: Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association. Circulation 2016
  9. 447–454. [CrossRef ] 10. Sultana C, Shen Y, Rattan V, Kalra VK. Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte-like HL-60 cells is linked to protein kinase C activation. J Cell Physiol 1996
  10. 477–487. [CrossRef ] 11. Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, Kissela BM, Kittner SJ, Lichtman JH, Lisabeth L